Tag Archives: CEOs
Unmet Need in the Migraine Space?
Allergan CEO David Pyott is bullish on Botox’s potential as a salve for chronic migraine. He’s also betting on a next-gen dihydroergotamine (DHE) – Levadex – from MAP Pharmaceuticals.
Posted in FDA, Global, Marketing, Regulatory, Strategy, Technology Also tagged Allergan, MAP Pharmaceuticals, Migraine, PDUFA 2 Comments
Medco CEO Champions Robots Over Pharmacists
The role of the pharmacist in positive health outcomes – and drug company profits – is often cited in discussions around adherence to medication regimens, holistic prescribing practices and the navigation of insurance payment structures.
In an attempt to demystify that role, Medco CEO David Snow told attendees at the Cleveland Clinic’s Medical Innovation Summit last [...]
Posted in Regulatory, Strategy, patient education, pricing Also tagged Medco, PBM, Pharmacists, Pharmacy 22 Comments

Fixing Innovation: Lilly's CEO Says Why, and How